Abstract
Lung cancer results in more patient deaths each year than any other cancer type. Additional treatment strategies are needed to improve clinical responses to approved treatment modalities and prevent the emergence of resistant disease. Catecholamines including norepinephrine and epinephrine are elevated as a result of chronic stress and mediate their physiological effects through activation of adrenergic receptors on target tissues. Lung cancer cells express β-adrenergic receptors (β-ARs), and numerous preclinical studies indicate that β2-AR signaling on lung cancer cells facilities cellular programs including proliferation, motility, apoptosis resistance, epithelial-to-mesenchymal transition, metastasis, and the acquisition of an angiogenic and immunosuppressive phenotype. Here, we review the preclinical and clinical evidence supporting a potential role for beta-blockers in improving the clinical outcome of lung cancer patients.

Catecholamines including norepinephrine and epinephrine act of β-ARs expressed on NSCLC tumor cells and activate pathways regulating tumor progression.



Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Al-Wadei HA, Al-Wadei MH, Masi T, Schuller HM (2010) Chronic exposure to estrogen and the tobacco carcinogen NNK cooperatively modulates nicotinic receptors in small airway epithelial cells. Lung Cancer 69:33–39
Al-Wadei HA, Plummer HK 3rd, Ullah MF, Unger B, Brody JR, Schuller HM (2012) Social stress promotes and gamma-aminobutyric acid inhibits tumor growth in mouse models of non-small cell lung cancer. Cancer Prev Res (Phila) 5:189–196
Al-Wadei HA, Al-Wadei MH, Schuller HM (2012a) Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One 7:e29915
Al-Wadei MH, Al-Wadei HA, Schuller HM (2012b) Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors alpha3, alpha5, and alpha7. Mol Cancer Res 10:239–249
Aydiner A, Ciftci R, Karabulut S, Kilic L (2013) Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer? Asian Pac J Cancer Prev 14:6109–6114
Banerjee J, Papu John AM, Schuller HM (2015) Regulation of nonsmall-cell lung cancer stem cell like cells by neurotransmitters and opioid peptides. Int J Cancer 137:2815–2824
Barbieri A, Bimonte S, Palma G, Luciano A, Rea D, Giudice A, Scognamiglio G, La Mantia E, Franco R, Perdona S, De Cobelli O, Ferro M, Zappavigna S, Stiuso P, Caraglia M, Arra C (2015) The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. Int J Oncol 47:527–534
Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K (2000) Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 8:154–164
Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, Ben-Eliyahu S (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15:2042–2052
Bleiker EM, Hendriks JH, Otten JD, Verbeek AL, van der Ploeg HM (2008) Personality factors and breast cancer risk: a 13-year follow-up. J Natl Cancer Inst 100:213–218
Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA (2017) Beta-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Res 77:5639–5651
Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V (2014) Perioperative beta-blocker use and survival in lung cancer patients. J Clin Anesth 26:106–117
Chang PY, Huang WY, Lin CL, Huang TC, Wu YY, Chen JH, Kao CH (2015) Propranolol reduces cancer risk: a population-based cohort study. Medicine (Baltimore) 94:e1097
Chaudhary KR, Yan SX, Heilbroner SP, Sonett JR, Stoopler MB, Shu C, Halmos B, Wang TJC, Hei TK, Cheng SK (2019) Effects of beta-adrenergic antagonists on Chemoradiation therapy for locally advanced non-small cell lung cancer. J Clin Med 8(5):E575
Chen D, Xing W, Hong J, Wang M, Huang Y, Zhu C, Yuan Y, Zeng W (2012) The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol 19:3556–3565
Choi MJ, Cho KH, Lee S, Bae YJ, Jeong KJ, Rha SY, Choi EJ, Park JH, Kim JM, Lee JS, Mills GB, Lee HY (2015) hTERT mediates norepinephrine-induced slug expression and ovarian cancer aggressiveness. Oncogene 34:3402–3412
Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18:1201–1206
Cremaschi GA, Fisher P, Boege F (1991) Beta-adrenoceptor distribution in murine lymphoid cell lines. Immunopharmacology 22:195–206
Daly CJ, McGrath JC (2011) Previously unsuspected widespread cellular and tissue distribution of beta-adrenoceptors and its relevance to drug action. Trends Pharmacol Sci 32:219–226
de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474–477
Dhabhar FS (2014) Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res 58:193–210
Duijts SF, Zeegers MP, Borne BV (2003) The association between stressful life events and breast cancer risk: a meta-analysis. Int J Cancer 107:1023–1029
Engelman JA, Janne PA (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14:2895–2899
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514
Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129:549–556
Garg J, Feng YX, Jansen SR, Friedrich J, Lezoualc'h F, Schmidt M, Wieland T (2017) Catecholamines facilitate VEGF-dependent angiogenesis via beta2-adrenoceptor-induced Epac1 and PKA activation. Oncotarget 8:44732–44748
Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG (1988) Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078–4082
Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S (2010) Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 184:2449–2457
Granot Z (2019) Neutrophils as a therapeutic target in cancer. Front Immunol 10:1710
Hamer M, Chida Y, Molloy GJ (2009) Psychological distress and cancer mortality. J Psychosom Res 66:255–258
Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, Towers AJ, Williams B, Lam CM, Xiao K, Shenoy SK, Gregory SG, Ahn S, Duckett DR, Lefkowitz RJ (2011) A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature 477:349–353
Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP, Wicha MS (2013) Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 19:1972–1980
Herve J, Dubreil L, Tardif V, Terme M, Pogu S, Anegon I, Rozec B, Gauthier C, Bach JM, Blancou P (2013) beta2-Adrenoreceptor agonist inhibits antigen cross-presentation by dendritic cells. J Immunol 190:3163–3171
Hulsurkar M, Li Z, Zhang Y, Li X, Zheng D, Li W (2017) Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1. Oncogene 36:1525–1536
Jang HJ, Boo HJ, Lee HJ, Min HY, Lee HY (2016) Chronic stress facilitates lung tumorigenesis by promoting exocytosis of IGF2 in lung epithelial cells. Cancer Res 76:6607–6619
Jean Wrobel L, Bod L, Lengagne R, Kato M, Prevost-Blondel A, Le Gal FA (2016) Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. Oncotarget 7:77825–77837
Kaira K, Kamiyoshihara M, Kawashima O, Endoh H, Imaizumi K, Sugano M, Tanaka S, Fujita A, Kogure Y, Shimizu A, Oyama T, Asao T, Shimizu K, Mogi A (2019) Prognostic impact of beta2 adrenergic receptor expression in surgically resected pulmonary pleomorphic carcinoma. Anticancer Res 39:395–403
Kemp VH, Hatmaker DD (1989) Stress and social support in high-risk pregnancy. Res Nurs Health 12:331–336
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792
Kohm AP, Sanders VM (1999) Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrine depletion in vivo. J Immunol 162:5299–5308
Kondratenko TY, Zacharova IV, Kuzina NV, Katukov VY, Severin ES, Kornilova ZC, Perelman MI (1993) Alterations in human lung adrenergic receptors in cancer. Biochem Mol Biol Int 29:123–130
Lin CS, Lin WS, Lin CL, Kao CH (2015) Carvedilol use is associated with reduced cancer risk: a nationwide population-based cohort study. Int J Cardiol 184:9–13
Liu D, Yang Z, Wang T, Yang Z, Chen H, Hu Y, Hu C, Guo L, Deng Q, Liu Y, Yu M, Shi M, Du N, Guo N (2016) beta2-AR signaling controls trastuzumab resistance-dependent pathway. Oncogene 35:47–58
Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 9:4514–4521
Maestroni GJM (2019) Adrenergic modulation of hematopoiesis. J Neuroimmune Pharmacol. https://doi.org/10.1007/s11481-019-09840-7
McEwen BS (2002) Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. Neurobiol Aging 23:921–939
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645–2652
Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66:807–822
Musselman RP, Bennett S, Li W, Mamdani M, Gomes T, van Walraven C, Boushey R, Al-Obeed O, Al-Omran M, Auer RC (2018) Association between perioperative beta blocker use and cancer survival following surgical resection. Eur J Surg Oncol 44:1164–1169
Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK (2007) Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282:29919–29926
Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV (2017) Stress hormones promote EGFR inhibitor resistance in NSCLC: implications for combinations with beta-blockers. Sci Transl Med 9:eaao4307
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
Park PG, Merryman J, Orloff M, Schuller HM (1995) Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 55:3504–3508
Penninx BW, Guralnik JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ (1998) Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90:1888–1893
Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1:628–638
Qiao G, Chen M, Bucsek MJ, Repasky EA, Hylander BL (2018) Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response. Front Immunol 9:164
Qin JF, Jin FJ, Li N, Guan HT, Lan L, Ni H, Wang Y (2015) Adrenergic receptor beta2 activation by stress promotes breast cancer progression through macrophages M2 polarization in tumor microenvironment. BMB Rep 48:295–300
Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Tasken KA (2008) Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate 68:1133–1142
Robinson JD, Cinciripini PM (2006) The effects of stress and smoking on catecholaminergic and cardiovascular response. Behav Med 32:13–18
Sapolsky RM (1993) Why zebras don’t get ulcers: a guide to stress, stress-related disease and coping. W. H. Freeman & Co, New York
Schuller HM, Cekanova M (2005) NNK-induced hamster lung adenocarcinomas over-express beta2-adrenergic and EGFR signaling pathways. Lung Cancer 49:35–45
Schuller HM, Tithof PK, Williams M, Plummer H 3rd. (1999) The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59:4510–4515
Seiffert K, Hosoi J, Torii H, Ozawa H, Ding W, Campton K, Wagner JA, Granstein RD (2002) Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol 168:6128–6135
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334
Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG (2011) Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 72:157–161
Shakhar G, Ben-Eliyahu S (1998) In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 160:3251–3258
Shan T, Cui X, Li W, Lin W, Li Y, Chen X, Wu T (2014) Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines. Cancer Sci 105:847–856
Shang ZJ, Liu K, Liang DF (2009) Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 38:371–376
Shao C, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez-Canales J, Liu H, Behrens C, Shay JW, Wistuba II, Minna JD (2014) Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res 20:4154–4166
Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, Zhang H, Yong Z, Gong Z, Song L, Yu M, Hu M, Xia Q, Shen B, Guo N (2011) The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat 125:351–362
Shin VY, Wu WK, Chu KM, Koo MW, Wong HP, Lam EK, Tai EK, Cho CH (2007) Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol Sci 96:21–29
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34
Singh S, Chellappan S (2014) Lung cancer stem cells: molecular features and therapeutic targets. Mol Asp Med 39:50–60
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70:7042–7052
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939–944
Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890
Van Tits LJ, Michel MC, Grosse-Wilde H, Happel M, Eigler FW, Soliman A, Brodde OE (1990) Catecholamines increase lymphocyte beta 2-adrenergic receptors via a beta 2-adrenergic, spleen-dependent process. Am J Phys 258:E191–E202
Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR (2013) Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312–1319
Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Mppv H-S, Vissers PAJ, Brenner H (2017) Pre- and post-diagnostic beta-blocker use and lung cancer survival: a population-based cohort study. Sci Rep 7:2911
Weiner H (1992) Perturbing the organism: the biology of stressful experience. University of Chicago Press, Chicago
Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH (2007) Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol 221:261–267
Wu X, Zang W, Cui S, Wang M (2012) Bioinformatics analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. Eur Rev Med Pharmacol Sci 16:1582–1587
Wu X, Liu BJ, Ji S, Wu JF, Xu CQ, Du YJ, You XF, Li B, Le JJ, Xu HL, Duan XH, Dong JC (2015) Social defeat stress promotes tumor growth and angiogenesis by upregulating vascular endothelial growth factor/extracellular signal-regulated kinase/matrix metalloproteinase signaling in a mouse model of lung carcinoma. Mol Med Rep 12:1405–1412
Xia Y, Wei Y, Li ZY, Cai XY, Zhang LL, Dong XR, Zhang S, Zhang RG, Meng R, Zhu F, Wu G (2019) Catecholamines contribute to the neovascularization of lung cancer via tumor-associated macrophages. Brain Behav Immun 81:111–121
Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357–10364
Yang EV, Donovan EL, Benson DM, Glaser R (2008) VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav Immun 22:318–323
Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 23:267–275
Yang P, Deng W, Han Y, Shi Y, Xu T, Shi J, Elhalawani H, Zhao Y, Xie X, Lou F, Zhang R, Jin H (2017) Analysis of the correlation among hypertension, the intake of beta-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer. Am J Cancer Res 7:946–954
Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R (2010) TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 107:15535–15540
Yazawa T, Kaira K, Shimizu K, Shimizu A, Mori K, Nagashima T, Ohtaki Y, Oyama T, Mogi A, Kuwano H (2016) Prognostic significance of beta2-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res 8:5059–5070
Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L (2012) Inhibition of CK2alpha down-regulates hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One 7:e38996
Zhang J, Deng YT, Liu J, Wang YQ, Yi TW, Huang BY, He SS, Zheng B, Jiang Y (2016) Norepinephrine induced epithelial-mesenchymal transition in HT-29 and A549 cells in vitro. J Cancer Res Clin Oncol 142:423–435
Funding
This work was funded by Lung SPORE grant 5 P50 CA070907, Lung Cancer Moon Shot Program, NIH CCSG (CA016672), and the Hanlon Fund. Figures were generated using BioRender.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
MN and JVH have filed a patent for the use of poziotinib for treating EGFR and HER2 mutant cancers, and licensed the technology to Spectrum Pharmaceuticals. JVH also has/had the following disclosures: grant or research support from AstraZeneca, Bayer, and GlaxoSmithKline and has served on advisory committees for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exelixis, Hengrui Therapeutics, Genentech, GSK, Guardant Health, Lilly, Novartis, Spectrum, Takeda, and Synta. XL is a consultant for Eli Lilly and AztraZeneca.
Ethical Approval
No animals were utilized in this manuscript.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nilsson, M.B., Le, X. & Heymach, J.V. β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. J Neuroimmune Pharmacol 15, 27–36 (2020). https://doi.org/10.1007/s11481-019-09891-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-019-09891-w